We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Repligen Corp | NASDAQ:RGEN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.32 | 4.43% | 125.32 | 120.50 | 125.00 | 125.40 | 120.50 | 121.10 | 1,505,719 | 23:09:12 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On June 13, 2024, Repligen Corporation (“Repligen”) issued a press release announcing that Tony J. Hunt will transition from his role as Repligen’s Chief Executive Officer to Executive Chair, and that Olivier Loeillot, Repligen’s President and Chief Commercial Officer, has been appointed as his successor, effective September 1, 2024. Repligen also announced that, as part of the transition, Karen A. Dawes, the current Chair of the Repligen board of directors, will assume the role of Lead Independent Director, also effective September 1, 2024.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Exhibit No. |
Description | |
99.1 | Press release issued by Repligen Corporation on June 13, 2024 (furnished herewith). | |
104 | Cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REPLIGEN CORPORATION | ||||||
Dated: June 13, 2024 | By: | /s/ Tony J. Hunt | ||||
Tony J. Hunt | ||||||
Chief Executive Officer |
Exhibit 99.1
|
Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 |
REPLIGEN ANNOUNCES CEO TRANSITION PLAN
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024
WALTHAM, Mass., June 13, 2024 Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors (Board) has approved the planned transition of Tony J. Hunt from Chief Executive Officer (CEO) to Executive Chair, effective September 1, 2024. The Companys Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.
Mr. Hunt has served as Chief Executive Officer and a member of the Companys Board of Directors since May 2015, successfully leading the Company to innovation leadership in bioprocessing. Under his direction, the Company has enjoyed consistent above-industry growth through disciplined acquisitions (M&A), internal product development (R&D), commercial execution and operational excellence. During Mr. Hunts tenure as CEO, Repligens revenue grew from approximately $63 million in 2014 to $639 million in 2023, representing an average annual growth rate of over 30% over the nine-year period.
Karen A. Dawes, current Board Chair at Repligen, stated, Over the past two years, the Repligen Board has developed a leadership succession plan to provide for the Companys ongoing success. Elevating Tony Hunt to Executive Chair and promoting Olivier Loeillot to CEO ensures that we will continue to have a clear strategic vision and achieve our long-term goals. Tony has been an outstanding CEO and we thank him for his leadership and continued commitment to the Company. Olivier, given his exceptional experience and the positive impact he has made since joining Repligen, is an ideal successor to Tony. The Board is confident that he will build on our strong foundation and successfully lead Repligen through the next phase of growth.
Mr. Loeillot currently oversees the Companys four business units and the global commercial organization. His focus since joining Repligen has been on driving the commercial and corporate key accounts strategy, participating in strategic planning and evaluating potential business development opportunities. A nearly 30-year industry veteran, Mr. Loeillot previously served for a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the multi-billion dollar bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing.
1
Olivier Loeillot, President and Chief Commercial Officer at Repligen, said, I am delighted and honored to take on the leadership role of President and CEO. Repligen is highly regarded in the bioprocessing industry and has achieved remarkable success under Tonys leadership. Since joining this results-focused team, I have been very impressed with the companys culture of innovation, commitment to its employees and customers, and its drive for excellence. I look forward to working with Tony and the Board to lead this high-performing organization to an even more successful future.
Tony J. Hunt, current CEO at Repligen, said, It has been my privilege to lead Repligen for over nine years and execute on the vision we set to bring disruptive, high value bioprocessing technologies to market. Having known and respected Olivier for many years and now having worked directly with him over the past months I share the Boards confidence that Olivier is an excellent choice for the CEO role and for the future of Repligen. As Executive Chair, I look forward to working with Olivier and focusing on corporate strategy, new product and business opportunities.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn.
This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like believe, expect, may, will, should, seek, or could and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.
2
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
# # #
3
Document and Entity Information |
Jun. 13, 2024 |
---|---|
Cover [Abstract] | |
Entity Registrant Name | REPLIGEN CORP |
Amendment Flag | false |
Entity Central Index Key | 0000730272 |
Document Type | 8-K |
Document Period End Date | Jun. 13, 2024 |
Entity Incorporation State Country Code | DE |
Entity File Number | 000-14656 |
Entity Tax Identification Number | 04-2729386 |
Entity Address, Address Line One | 41 Seyon Street |
Entity Address, Address Line Two | Bldg. 1 |
Entity Address, Address Line Three | Suite 100 |
Entity Address, City or Town | Waltham |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02453 |
City Area Code | (781) |
Local Phone Number | 250-0111 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.01 per share |
Trading Symbol | RGEN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
1 Year Repligen Chart |
1 Month Repligen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions